% | $
Quotes you view appear here for quick access.

Mindspeed Technologies, AŞ Message Board

  • fdaplayq fdaplayq Nov 6, 2013 9:35 AM Flag

    IGXT (MC $27 M) PDUFA Date on February 3 // 10 Dugs in Late Stage = 1000% ++Potential !!!

    Unknown Gem with Brutal Upside Potential ...GLTA

    2 Big Drugs awaiting FDA approval another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .

    NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
    (According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)

    IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
    (According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)

    Only 20 M on the float ..IGXT has the Potential to hit $8++ within 2 Year ! GLTA

    Intelgenx (IGXT)

    Market Cap : $27 M
    Cash: $3 M

    Burn-Rate : $2 M a year
    Shares Out : 51 M ( 30 M shares are held by Investors )

    IGXT´s Monster Pipeline :

    Product ......Application......... Status of Development

    INT0004/2006 Antidepressant -- US launch in 4Q 2012

    INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014

    INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014

    INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014

    INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA

    INT0020/2010 Insomnia -- in Pivotal Study

    INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

    INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

    INT0030/2011 Animal health -- in Pivotal Study

    INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study